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Aims Resting heart rate is a promising modifiable cardiovascular risk marker in older adults, but the mechanisms linking
heart rate to cardiovascular disease are not fully understood. We aimed to assess the association between resting
heart rate and incident heart failure (HF) and cardiovascular mortality, and to examine whether these associations
might be attributable to systemic inflammation and endothelial dysfunction.
Methods
and results
We studied 4084 older adults aged 70–82 years with known cardiovascular risk factors or previous cardiovascular
disease, without pre-existing HF or beta-blockers in the PROSPER study. Over a 3.2-year follow-up period, we exam-
ined incident HF hospitalization and cardiovascular mortality according to resting heart rate, along with C-reactive
protein (CRP), interleukin-6 (IL-6), tissue plasminogen activator (tPA), and von Willebrand factor (vWf). Mean
heart rate was 67 b.p.m. for men and 70 b.p.m. for women. CRP, IL-6, tPA, and vWf levels were all positively corre-
lated with heart rate. After multivariate adjustment, heart rate was associated with HF hospitalization [hazard ratio
(HR) 1.78 for highest vs. lowest distribution third, 95% confidence interval (CI) 1.21–2.63, P ¼ 0.003] and cardiovas-
cular mortality (HR 1.74, 95% CI 1.23–2.47, P ¼ 0.002). Further adjustment for both IL-6 and vWf levels decreased
HR to 1.60 (95% CI 1.08–2.38, P ¼ 0.020) for HF and to 1.50 (95% CI 1.04–2.15, P ¼ 0.028) for cardiovascular
mortality.
Conclusion Increased heart rate is associated with increased systemic inflammation and endothelial dysfunction. These factors are
likely to contribute to, but do not fully explain, the risk of HF and cardiovascular death associated with increased
heart rate in older age.
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For . 20 years, observational studies have reported an association
between elevated resting heart rate and cardiovascular disease.1,2
The underlying explanations for these associations are still
unclear, and uncertainty remains about the causal role of heart
rate in the development of cardiovascular disease.3 However,
resting heart rate appears to be a promising and modifiable cardio-
vascular risk factor in older adults, in whom traditional cardiovas-
cular risk factors such as cholesterol level and blood pressure have
a lower predictive capacity.4
There are many hypothetical mechanisms through which ele-
vated heart rate might directly affect cardiovascular or heart
failure risk, including systemic inflammation and endothelial dys-
function.5 Systemic inflammation as measured by inflammatory
markers such as C-reactive protein (CRP) or interleukin-6 (IL-6)
is an important factor in the pathogenesis of cardiovascular
disease.6,7 Previous cross-sectional studies have suggested a link
between heart rate and systemic inflammation through a mechan-
ism related to autonomic imbalance.8,9 Markers of endothelial dys-
function, as measured by von Willebrand factor (vWf) or tissue
plasminogen activator (tPA), have gained interest in the pathogen-
esis of cardiovascular disease,10 and might be associated with
resting heart rate.11 Thus, the interrelationship between resting
heart rate, systemic inflammation, and endothelial dysfunction
might play a key role in the development of cardiovascular
disease, and previous epidemiological data have failed to demon-
strate a cause–effect relationship because of potential residual
confounding.12,13
Therefore, we studied the association between resting heart
rate, incident heart failure, and cardiovascular mortality in the
PROSPER study, a large prospective study of older men and
women, and examined whether any associations might be attribut-
able to inflammation or endothelial dysfunction.
Methods
Study population
Participants were part of the PROSPER trial designed to examine the
benefits of pravastatin vs. placebo in adults aged 70–82 years old.14
Details of the design, data collection, and eligibility criteria have been
previously described.15 Briefly, 5804 individuals aged 70–82 years,
and sufficiently mobile to attend visits at their general practitioner’s
office or the study centre, were randomized to 40 mg pravastatin or
placebo in The Netherlands, Scotland, and Ireland. Only participants
with a history of vascular disease, defined as coronary, cerebral, or
peripheral artery disease, or those with known cardiovascular risk
factors, such as smoking, hypertension, or diabetes, were enrolled. Par-
ticipants with symptomatic congestive heart failure (NYHA functional
class III or IV) or ECG evidence of AF were excluded, as well as those
with poor cognitive function [Mini Mental State Examination (MMSE)
score ,24]. The Medical Ethics Committee of all centres approved
the study, and informed consent was obtained from all participants.
From the original study sample of 5804 individuals, we excluded 120
participants with missing heart rate measurements at baseline, four
participants with baseline AF (who were protocol violators), and
149 taking antiarrhythmic drugs and 1447 taking beta-blockers,
because of the effects of antiarrhythmic drugs and beta-blockers on
heart rate. Hence, the final sample of our study was 4084 participants.
Resting heart rate
Resting heart rate (b.p.m.) was automatically measured from a 12-lead
ECG recorded in the morning as part of the first enrolment visit, along
with fasting venous blood sample collection, to limit circadian variabil-
ity.15,16 All ECGs were interpreted using the same software, which
produced all measurements including heart rate, as previously
described.16
Inflammation and endothelial dysfunction
markers
At baseline, vWf, tPA, and IL-6 were measured with an enzyme-linked
immunosorbent assay; Biopool AB was used for tPA, rabbit antihuman
polyclonal antibodies (Dako) were used for vWf, and R&D Systems
was used for IL-6, as previously reported.17,18 CRP was measured at




We examined incident heart failure hospitalization and cardiovascular
mortality as previously defined.14 Heart failure hospitalizations were
defined based on a combination of symptoms (e.g. shortness of
breath) and signs, including chest radiograph with fluid congestion or
echocardiogram with severely diminished LV function.15 Cardiovascu-
lar mortality was the combined endpoint of coronary heart disease
death, fatal stroke, and other vascular death. All outcomes were adju-
dicated by an expert committee blinded to randomized study medica-
tion and using pre-defined criteria.14
Baseline covariates
Diabetes at baseline was defined as self-reported diagnosis, use of antidia-
betic drugs, or as fastingblood glucoseof ≥ 7.0 mmol/L,or ≤ 11.1 mmol/L
when fasting status was uncertain.15 Smoking was defined as never, current,
or former. Baseline lipids, creatinine, estimated glomerular filtration rate
(eGFR), thyroid-stimulating hormone (TSH), blood pressure, and body
mass index (BMI) measurements, education, alcohol intake, MMSE score,
and medication use were assessed as previously reported.14,15,19,20
Statistical analyses
Resting heart rate values were grouped into thirds of their distribution,
as pre-defined beforehand. This was done separately for women and
men because women have a higher resting heart rate than men.21
One-way analysis of variance (ANOVA) and x2 tests were used for
group comparisons. Covariates associated with heart rate were add-
itionally examined in a multivariate regression model with stepwise
forward selection. We applied a log transformation for CRP and IL-6
concentrations, and report geometric means, because of right-skewed
distribution. Kaplan–Meier curves were used to illustrate cumulative
incidence of heart failure and survival graphically. The associations
between gender-specific heart rate thirds and the endpoints were
examined using age- and multivariate-adjusted Cox proportional
hazards models, with the lowest heart rate group as the reference
group. P-values were computed by introducing heart rate as a continu-
ous variable in each model. For the multivariate basic model, potential
confounders were determined by biological plausibility, and we
retained age, smoking status, baseline diabetes, history of vascular
disease, history of angina, hypertension, BMI, HDL-cholesterol, TSH,
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Table 1 Baseline characteristics of the 4084 PROSPER participants according to gender-specific heart rate thirds
Low heart rate third
(n 5 1391)
Middle heart rate third
(n 5 1421)
High heart rate third
(n 5 1272)
P-value
Heart rate, b.p.m. 57.5 (5.1) 68.5 (3.2) 81.8 (7.7)
Demographics
Age, years 75.2 (3.3) 75.3 (3.4) 75.4 (3.4) 0.577
Female, n (%) 716 (51.5) 714 (50.2) 638 (50.2) 0.743
Education, years 15.2 (2.1) 15.1 (2.0) 15.0 (1.9) 0.020
Smoking status, n (%) 0.112
Never 418 (30.0) 427 (30.0) 404 (31.8)
Former 552 (39.7) 509 (35.8) 460 (36.2)
Current 421 (30.3) 485 (34.1) 408 (32.1)
Alcohol consumption, drinks/week 5.2 (8.6) 5.5 (9.9) 5.5 (9.8) 0.629
Co-morbidities
Hypertension, n (%) 745 (53.6) 770 (54.2) 723 (56.8) 0.200
Diabetes, n (%) 114 (8.2) 170 (12.0) 179 (14.1) < 0.001
History of vascular disease, n (%)a 616 (44.3) 586 (41.2) 503 (39.6) 0.041
History of coronary artery disease, n (%)b 208 (14.9) 171 (12.0) 179 (14.1) 0.069
History of angina, n (%) 363 (26.1) 321 (22.6) 269 (21.2) 0.008
History of stroke or TIA, n (%) 163 (11.7) 163 (11.5) 143 (11.2) 0.928
History of peripheral artery disease, n (%)c 100 (7.2) 122 (8.6) 119 (9.4) 0.412
Lower MMSE score, n (%)d 413 (29.7) 459 (32.3) 439 (34.5) 0.028
Objective measures
Systolic blood pressure, mmHg 152.6 (20.9) 154.5 (21.2) 156.6 (21.6) < 0.001
Diastolic blood pressure, mmHg 82.5 (10.9) 84.0 (11.3) 85.4 (11.7) < 0.001
Weight, kg 72.4 (12.7) 73.3 (13.1) 73.2 (14.3) 0.142
Height, cm 165.5 (9.4) 165.4 (9.7) 164.7 (9.4) 0.060
Body mass index, kg/m2 26.4 (4.0) 26.7 (4.1) 26.9 (4.6) 0.004
Total cholesterol, mmol/L 5.7 (0.9) 5.7 (0.9) 5.7 (0.9) 0.559
LDL-cholesterol, mmol/L 3.8 (0.8) 3.8 (0.8) 3.7 (0.8) 0.070
HDL-cholesterol, mmol/L 1.3 (0.3) 1.3 (0.4) 1.3 (0.4) 0.013
Triglycerides, mmol/L 1.5 (0.7) 1.5 (0.7) 1.5 (0.7) 0.216
Fasting glucose, mmol/L 5.3 (1.2) 5.4 (1.4) 5.6 (1.7) < 0.001
Creatinine, mmol/L 100.5 (21.8) 100.4 (21.6) 100.8 (22.0) 0.882
eGFR, mL/min 60.3 (13.8) 60.7 (14.2) 60.5 (14.7) 0.761
TSH, mIU/L 2.4 (2.2) 2.3 (2.1) 2.2 (2.0) 0.150
CRP, mg/L 2.7 (2.8) 3.0 (3.2) 3.8 (3.3) < 0.001
IL-6, pg/mL 2.4 (1.5) 2.6 (1.9) 2.9 (2.1) < 0.001
tPA, ng/mL 10.5 (3.8) 10.7 (4.0) 11.3 (4.1) < 0.001
vWf, IU/dL 137.4 (45.2) 141.3 (46.3) 146.7 (47.7) < 0.001
Medication use
Pravastatin, n (%) 695 (50.0) 732 (51.5) 651 (51.2) 0.373
Aspirin, n (%) 501 (36.0) 463 (32.6) 399 (31.4) 0.029
Nitrates, n (%) 262 (18.8) 223 (15.7) 182 (14.3) 0.005
Diuretics, n (%) 528 (38.0) 526 (37.0) 523 (41.2) 0.076
Calcium channel blockers, n (%) 378 (21.2) 350 (24.6) 319 (25.1) 0.261
ACE inhibitors, n (%) 229 (16.5) 228 (16.1) 244 (19.2) 0.068
ARBs, n (%) 33 (2.4) 34 (2.4) 25 (2.0) 0.707
Other antihypertensive drugs, n (%) 43 (3.1) 56 (3.9) 61 (4.8) 0.077
Thyroid hormone, n (%) 67 (4.8) 69 (4.9) 44 (3.4) 0.139
Data are given as mean (standard deviation) unless otherwise indicated.
CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; IL-6, interleukin-6; MMSE, Mini Mental State Examination; TSH, thyroid-stimulating hormone; TIA, transient
ischaemic attack; tPA, tissue plasminogen activator; vWf, von Willebrand factor.
aVascular disease defined as history of coronary, cerebral, or peripheral artery disease.
bCoronary artery disease defined as history of myocardial infarction, PCI, or coronary artery bypass surgery.
cPeripheral artery disease defined as history of claudication or peripheral vascular surgery.
dMMSE score of 24–27. Participants with poor cognitive function were excluded (MMSE ,24).
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and eGFR. We further adjusted the model for randomization code
(pravastatin), and use of aspirin, nitrates, diuretics, ACE inhibitors,
and ARBs to account for medication. To assess the effect of inflamma-
tion and endothelial dysfunction, we further adjusted the basic model
for CRP and IL-6, and with tPA and vWf, respectively. Finally, we
examined a multivariate model using the inflammatory marker and
the endothelial dysfunction marker with the strongest association
(IL-6 and vWf), as well as a multivariate model using all inflammatory
and endothelial dysfunction markers. Subgroup analyses were con-
ducted in men and women separately, and in participants with low
CRP levels (,2 mg/L), moderate CRP (between 2 and 5 mg/L), or ele-
vated CRP levels (.5 mg/L), as well as across strata of IL-6, tPA, and
vWf thirds, and groups defined by the use of statin or placebo. The sig-
nificance of the multiplicative interaction term between heart rate as a
continuous variable and subgroups in the multivariate model was
reported. We further stratified our results in adults without and
with pre-existing cardiovascular disease or diabetes. All analyses
were conducted using Stata 12.0 (Stata Corp, College Station, TX,
USA), all statistical tests were two-sided, and P , 0.05 was considered
statistically significant.
Results
Mean age of the participants was 75 years and 51% were female.
Table 1 reports baseline characteristics of the study population,
over thirds of heart rate. In men, resting heart rate values
were , 61 b.p.m. for the first third, 62–71 b.p.m. for the
second, and ≥ 72 b.p.m. for the third. In women, cut-offs
were , 65 b.p.m., 66–74 b.p.m., and ≥ 75 b.p.m., respectively.
Both inflammatory markers (CRP and IL-6) and endothelial dys-
function markers (tPA and vWf) were significantly increased
over thirds of resting heart rate. Participants in the highest heart
rate third were also more likely to have diabetes, a higher blood
pressure, and a higher BMI compared with participants in the
lowest heart rate group. In contrast, they were less likely to have
pre-existing vascular disease, or a history of angina, and to be
treated by aspirin or nitrates. In multivariate analyses, CRP, IL-6,
tPA, and vWf all remained independently associated with resting
heart rate (all P , 0.001; Supplementary material, Table S1).
Figure 1 Cumulative incidence of heart failure hospitalization and cardiovascular mortality over the 3-year follow-up period depending on
sex-specific heart rate groups.
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The incidence of heart failure hospitalization was 12.9 per 1000
person-years [95% confidence interval (CI) 11.1–15.0] and was
higher in men (14.4 per 1000 man-years, 95% CI 11.7–17.7)
than in women (11.5 per 1000 woman-years, 95% CI 9.2–14.4),
although without statistical difference (log-rank test P ¼ 0.14).
A resting heart rate in the highest third vs. the lowest third was
associated with a similar increased risk of heart failure hospitaliza-
tion [multivariate-adjusted hazard ratio (HR) of 1.78, 95% CI 1.21–
2.63, P ¼ 0.003] and cardiovascular mortality (HR 1.74, 95% CI
1.23–2.47, P ¼ 0.002) (Figure 1, Table 2). Adults in the middle
heart rate group also had a higher risk of heart failure and cardio-
vascular mortality, but without reaching statistical significance,
compared with those in the lowest heart rate group. The
multivariate-adjusted HR per b.p.m. higher heart rate was 1.023
(95% CI 1.010–1.036) for heart failure and 1.022 (95% CI
1.010–1.033) for cardiovascular mortality. Similar figures were
found after further adjustment for medication, including the ran-
domization allocation for statin use or placebo. Further adjustment
for inflammatory markers, CRP or IL-6, and further adjustment
for endothelial dysfunction markers, tPA or vWf, only slightly
decreased HRs (Table 2). Further adjustment for both IL-6 and
vWf levels decreased the HR (highest vs. lowest third of heart
rate) for heart failure to 1.60 (95% CI 1.08–2.38), p ¼ 0.020,
and the HR for cardiovascular mortality to 1.50 (95% CI 1.04–
2.15), P ¼ 0.028.
Stratified analyses
The associations between resting heart rate and heart failure or
cardiovascular mortality reached statistical significance in men
only, but there was no significant interaction of gender on the as-
sociation between heart rate and heart failure or cardiovascular
mortality (Figure 2). For one unit increase in heart rate, a similar
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Risk of heart failure and cardiovascular mortality depending on resting heart rate
Low heart rate third
(n 5 1391)
Middle heart rate third
(n 5 1421)




No. of events 43 57 67
Incidence rate, per 1000 person-years 9.6 12.6 17.0
Age-adjusted HR (95% CI) 1.00 (referent) 1.30 (0.88–1.94) 1.75 (1.19–2.57) ,0.001
Multivariate-adjusted HR (95% CI)a 1.00 (referent) 1.32 (0.88–1.96) 1.78 (1.21–2.63) 0.001
Additional adjustment for
treatmentb
1.00 (referent) 1.36 (0.91–2.02) 1.80 (1.22–2.65) 0.001
Additional adjustment for CRP 1.00 (referent) 1.31 (0.88–1.96) 1.75 (1.19–2.60) 0.001
Additional adjustment for IL-6 1.00 (referent) 1.28 (0.86–1.92) 1.64 (1.11–2.44) 0.003
Additional adjustment for tPA 1.00 (referent) 1.25 (0.83–1.88) 1.82 (1.23–2.70) ,0.001
Additional adjustment for vWf 1.00 (referent) 1.24 (0.82–1.86) 1.75 (1.18–2.58) 0.001
Additional adjustment for both IL-6
and vWf
1.00 (referent) 1.22 (0.81–1.83) 1.60 (1.08–2.38) 0.004
Additional adjustment for all
markersc
1.00 (referent) 1.20 (0.79–1.80) 1.62 (1.09–2.41) 0.003
Cardiovascular mortality
No. of deaths 53 63 84
Incidence rate, per 1000 person-years 11.7 13.7 20.9
Age-adjusted HR (95% CI) 1.00 (referent) 1.18 (0.82–1.69) 1.78 (1.26–2.51) ,0.001
Multivariate-adjusted HR (95% CI)a 1.00 (referent) 1.13 (0.78–1.64) 1.74 (1.23–2.47) ,0.001
Additional adjustment for
treatmentb
1.00 (referent) 1.15 (0.79–1.66) 1.73 (1.22–2.45) 0.001
Additional adjustment for CRP 1.00 (referent) 1.11 (0.76–1.60) 1.61 (1.13–2.30) 0.003
Additional adjustment for IL-6 1.00 (referent) 1.11 (0.76–1.60) 1.57 (1.10–2.24) 0.004
Additional adjustment for tPA 1.00 (referent) 1.11 (0.77–1.62) 1.67 (1.17–2.38) 0.001
Additional adjustment for vWf 1.00 (referent) 1.14 (0.78–1.66) 1.65 (1.15–2.36) 0.001
Additional adjustment for both IL-6
and vWf
1.00 (referent) 1.08 (0.74–1.58) 1.50 (1.04–2.15) 0.009
Additional adjustment for all
markersc
1.00 (referent) 1.05 (0.72–1.54) 1.48 (1.03–2.13) 0.010
CI, confidence interval; CRP, C-reactive protein; HR, hazard ratio; IL-6, interleukin-6; tPA, tissue plasminogen activator; vWf, von Willebrand factor.
aBasic model: adjusted for age, smoking status, diabetes, history of cardiovascular disease, history of angina, hypertension, body mass index, HDL-cholesterol, thyroid-stimulating
hormone, and glomerular filtration rate.
bBasic model plus additional adjustment for randomization group (pravastatin), aspirin, nitrate, calcium channel blocker, diuretic, ACE inhibitor, and ARB use.
cBasic model plus additional adjustment for CRP, IL-6, tPA, and vWf.
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2% increased risk for heart failure and cardiovascular mortality was
found across strata of inflammatory marker levels. Similar patterns
of risk for heart failure and cardiovascular mortality were also
found across strata of endothelial dysfunction markers. In the sub-
group with CRP levels ,2 mg/L, a lower risk of cardiovascular
mortality was found along with elevation of resting heart rate,
but the interaction term was not significant (P ¼ 0.42).
The increased heart failure and cardiovascular mortality risk
associated with elevated heart rate were present in older adults
without cardiovascular disease or diabetes, as well as in those
with pre-existing cardiovascular disease or diabetes, and further
adjustment for inflammatory markers or endothelial dysfunction
only slightly modified the estimates (Figure 3).
Discussion
In older adults at high cardiovascular risk, an elevated resting heart
rate was associated with an increased risk of incident heart failure
hospitalization and cardiovascular mortality. This increased risk
was independent of traditional cardiovascular risk factors and
was only partially explained by inflammatory and endothelial
dysfunction markers. The association was present in both the pres-
ence and absence of statin use, as well as pre-existing cardiovascu-
lar disease or diabetes. To our knowledge, our study is the first to
report an independent association between heart rate and heart
failure and cardiovascular mortality, in which markers of inflamma-
tion and endothelial dysfunction were simultaneously assessed.
These results emphasize the strength of resting heart rate ‘per
se’ as a cardiovascular risk factor among older adults, and adds im-
portant information to disentangle the pathophysiological mechan-
isms linking resting heart rate and cardiovascular disease.
Resting heart rate is considered as a marker of autonomic
nervous system activity, and an elevated heart rate implies sympa-
thetic hyperactivity.5 This imbalance has been proposed to explain
the development of cardiovascular disease, but the exact mechan-
isms are still uncertain.3 Inflammatory markers such as CRP or IL-6
levels have been related to the autonomic nervous system in pre-
vious cross-sectional studies, suggesting that inflammation might
modify heart rate by impacting on the autonomic nervous
system.8,9 Our results confirm the close relationship between
resting heart rate and systemic inflammation, beyond fundamental
determinants of heart rate, such as gender or height, environmen-
tal factors such as smoking, blood pressure, hyperlipidaemia, dia-
betes, or other expected factors such as TSH levels. Although
inflammatory markers were independently associated with heart
rate, we additionally show that heart rate may influence the risk
of cardiac disease by pathways other than inflammation. Thus, sys-
temic inflammation may not be the only explanatory factor in the
worse prognosis of older adults with elevated heart rate.
Endothelial dysfunction generated by oscillatory shear stress due
to an elevated heart rate has also been identified as a biological
contributor to explain the development of cardiovascular
disease.3,5 tPA is involved in the conversion of plasminogen to
plasmin, and vWF mediates platelet adhesion and thrombosis.
Both tPA and vWf are produced by endothelial cells and can be
considered as markers of endothelial dysfunction.22,23 It has been
Figure 2 Multivariate-adjusted hazard ratio (HR) for one unit of increase in heart rate, according to gender, inflammatory markers levels,
endothelial dysfunction, and statin use. HRs are adjusted for age, sex, smoking status, diabetes, history of cardiovascular disease, history of
angina, hypertension, body mass index, HDL-cholesterol, thyroid-stimulating hormone, and glomerular filtration rate. CI, confidence interval;
CRP, C-reactive protein; IL6, interleukin-6; TPA, tissue plasminogen activator; vWF, von Willebrand factor.
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suggested that elevated heart rate could promote cardiac disease
through blood flow modification in the arteries, increasing oscilla-
tory endothelial shear stress, and influencing arterial stiffness and
LV afterload.3 In our study, resting heart rate was associated
with endothelial dysfunction independently of heart rate determi-
nants and systemic inflammation. These results are in line with
the hypothesis that haemodynamic mechanisms, such as oscillatory
shear stress, are mediators of the association between heart rate
and endothelial dysfunction.5,24 Over the study follow-up period,
we found no consistent evidence that endothelial dysfunction
could fully explain the link between resting heart rate and
cardiac disease. However, for values of vWf . 156 IU/dL, the
increased risk of cardiac disease associated with heart rate was
less pronounced, and we found a significant interaction term
between heart rate as a continuous variable and vWF levels
(P ¼ 0.044) for the risk of heart failure. This result might be due
to a chance event, because when using heart rate tertile-based cat-
egories, the interaction term between heart rate and vWf levels
was not significant (P ¼ 0.41).
Resting heart rate is easily measured in clinical practice and sys-
tematically recorded along with blood pressure measurement. In
older adults, traditional cardiovascular risk factors such as choles-
terol level and blood pressure have a lower or potentially different
predictive association,4 while we confirmed the increased cardiac
risk in older adults with elevated heart rate. This increased risk
was related to the level of heart rate, and only partially mediated
by systemic inflammation and endothelial dysfunction. Therefore,
heart rate appears to be a potential therapeutic target to reduce
the cardiovascular risk in older adults. Our study supports the ra-
tionale of designing clinical trials to test a specific heart rate-
lowering intervention to reduce the cardiac risk of older adults
with elevated resting heart rate. Many older adults with orthostatic
hypotension and elevated risk of falls a have contra-indication to
beta-blockers, and the risk of side effects with beta-blockers pre-
scribed as a preventive therapy for an elevated heart rate might
outweigh the benefits. Ivabradine is a new drug that specifically
inhibits the sinus node without influencing blood pressure.25,26 In
the SHIFT trail, the benefit of reducing heart rate with ivabradine
was the greatest with the highest heart rate levels,25 and ivabradine
is only licensed for heart failure patient with heart rate . 75 b.p.m.
In our study of older adults at high cardiovascular risk, 25% of
participants had a resting heart rate . 75 b.p.m. Future studies
should now evaluate the use of ivabradine among older adults
with elevated baseline heart rate.
Strengths of our data include the large population of older men
and women with biological phenotyping of subclinical inflammation
and endothelial dysfunction, the adjudication of clinical events with
well-defined criteria, and the possibility to compare the cardiovas-
cular impact of resting heart rate in statin and non-statin users.14
The use of statins seemed to modify the risk of heart failure asso-
ciated with increasing heart rate, but the interaction term did not
reach statistical difference (P ¼ 0.16). Experimental studies have
shown that statins can influence sympathetic activity.27 However,
since statins had no effect on the risk of heart failure in the
PROSPER trial during the study period, it seems unlikely that the
association between heart rate and heart failure is influenced by
statins.14 Our study also has some limitations. First, we excluded
a high number of participants using beta-blockers (26%) from the
original PROSPER sample. The use of beta-blockers was elevated
because participants were selected according to the presence of
cardiovascular risk factors or cardiovascular disease. However,
beta-blocker use might be an important confounder of the associ-
ation between heart rate and cardiovascular disease, which would
have greatly limited the interpretation of the results. In our study of
older adults at high cardiovascular risk, those with symptomatic
congestive heart failure were excluded. However, our population
certainly included participants with subclinical LV dysfunction. As
we did not characterize these individuals with echocardiography
at baseline, we cannot discard that an elevated heart rate was a
sign of mild heart failure, and not primarily an autonomic
nervous system issue. Further research about resting heart rate
is therefore merited along with BNP and echocardiography mea-
surements or in healthier older populations. The biological assess-
ment of endothelial dysfunction was undertaken with haemostatic/
thrombotic markers released by endothelial cells with an estab-
lished effect on vascular homeostasis, such as a platelet-activating
Figure 3 Risks of heart failure and cardiovascular mortality
associated with sex-specific heart rate groups in primary and sec-
ondary prevention, without and with adjustment for inflammation
and endothelial dysfunction. The first third of heart rate was the
referent group (T1). Primary/secondary prevention includes
older adults without/with cardiovascular disease or diabetes.
Squares (model 1) represent hazard ratios adjusted for age,
smoking status, diabetes, history of cardiovascular disease,
history of angina, hypertension, body mass index,
HDL-cholesterol, thyroid-stimulating hormone, and glomerular
filtration rate. Diamonds (model 2) represents hazards ratios
additionally adjusted for interleukin-6 and von Willebrand
factor. CI, confidence interval.
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(vWf) and profibrinolytic effect (tPA).22,23 However, these
markers might not be appropriate to assess other important pro-
cesses linked to endothelial damage, such as adhesion and migra-
tion of leucocytes. Further studies should assess the role of cell
adhesion molecules in the observed associations.6 Finally, although
inflammation and endothelial dysfunction markers were measured
at the baseline visit along with baseline heart rate, they were mea-
sured only once, and this might not reflect the chronic underlying
conditions of the participants.
In conclusion, through a mechanism only partially linked to sys-
temic inflammation and endothelial dysfunction, resting heart rate
was an independent marker of incident heart failure and cardiovas-
cular mortality in old age.
Supplementary material
Supplementary material is available at European Journal of Heart
Failure online.
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